The prognostic value of the platelet-to-lymphocyte ratio in multiple myeloma patients treated with a bortezomib-based regimen
Scientific Reports,
Год журнала:
2025,
Номер
15(1)
Опубликована: Янв. 13, 2025
Multiple
myeloma
(MM)
is
the
second
most
common
hematological
malignancy.
Previous
studies
have
validated
prognostic
significance
of
platelet-to-lymphocyte
ratio
(PLR)
in
patients
with
certain
solid
tumors.
However,
relationship
between
PLR
and
prognosis
has
not
been
clearly
demonstrated.
In
our
study,
we
included
122
newly
diagnosed
MM
who
were
treated
bortezomib-based
chemotherapy.
These
divided
into
low-PLR
high-PLR
groups
based
on
their
initial
values.
We
compared
clinical
characteristics
two
utilized
restricted
cubic
splines
(RCSs)
regression
model
to
estimate
nonlinear
overall
survival
(OS)
patients.
The
results
showed
that
group
had
significantly
worse
OS
(P
=
0.00031)
progression-free
(PFS)
<
0.0001)
those
group.
Furthermore,
within
higher-risk
group,
a
low
was
also
associated
0.0037)
PFS
0.0048).
Therefore,
identified
as
an
independent
predictor
poor
RCS
curves
further
confirmed
significant
MM.
may
serve
indicator
for
undergoing
chemotherapy,
there
exists
crucial
these
Язык: Английский
Integrated bulk and single-cell profiling characterize sphingolipid metabolism in pancreatic cancer
BMC Cancer,
Год журнала:
2024,
Номер
24(1)
Опубликована: Ноя. 1, 2024
Abnormal
sphingolipid
metabolism
(SM)
is
closely
linked
to
the
incidence
of
cancers.
However,
role
SM
in
pancreatic
cancer
(PC)
remains
unclear.
This
study
aims
explore
significance
prognosis,
immune
microenvironment,
and
treatment
PC.
Язык: Английский
High-throughput screening for optimizing adoptive T cell therapies
Experimental Hematology and Oncology,
Год журнала:
2024,
Номер
13(1)
Опубликована: Ноя. 13, 2024
Abstract
Adoptive
T
cell
therapy
is
a
pivotal
strategy
in
cancer
immunotherapy,
demonstrating
potent
clinical
efficacy.
However,
its
limited
durability
often
results
primary
resistance.
High-throughput
screening
technologies,
which
include
both
genetic
and
non-genetic
approaches,
facilitate
the
optimization
of
adoptive
therapies
by
enabling
selection
biologically
significant
targets
or
substances
from
extensive
libraries.
In
this
review,
we
examine
advancements
high-throughput
technologies
their
applications
therapies.
We
highlight
use
for
cells,
tumor
other
promising
combination
strategies,
elucidate
role
identifying
small
molecules
targeted
delivery
systems
relevant
to
therapies,
providing
guidance
future
research
applications.
Язык: Английский